View links to journals and guidelines used in the resource

Aarestrup, F. M., Ahrens, P., Madsen, M., Pallesen, L. V., Poulsen, R. L. & Westh, H. (1996). Glycopeptide susceptibility among Danish Enterococcus faecium and Enterococcus faecalis isolates of animal and human origin and PCR identification of genes within the VanA cluster.  Antimicrobial Agents and Chemotherapy 40, Suppl. 8, 1938–40.

Andrews, N. J. (2002). Incidence of variant Creutzfeldt-Jakob disease onsets and deaths in the UK. January 1994 – June 2002.  PHLS Statistics Unit. [Online]. Available at: http://www.cjd.ed.ac.uk/cjdq34.htm.

Babini, G. S. & Livermore, D. M. (2000). Antimicrobial resistance amongst Klebsiella spp. collected from intensive care units in Southern and Western Europe in 1997–1998. Journal of Antimicrobial Chemotherapy 45, Suppl. 2, 183–9.

Bennett, A. D. & Shaw, W. V. (1983). Resistance to fusidic acid in Escherichia coli mediated by the type 1 variant of chloramphenicol acetyltransferase. A plasmid-encoded mechanism involving antibiotic binding. Biochemical Journal 215, Suppl. 1, 29–38.

Brown, P. (2001). Bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease. British Medical Journal 322, 841–4.

Brown, P. (2002). Drug therapy in human and experimental transmissible spongiform encephalopathy. Neurology 58, Suppl. 12, 1720–5.

Bruce, M. E., Will, R. G., Ironside, J. W., McConnell, I., Drummond, D., Suttie, A. et al. (1997). Transmissions to mice indicate that ‘new variant’ CJD is caused by the BSE agent. Nature 389, 498–501.

Carter, M. W., Oakton, K. J., Warner, M. & Livermore, D. M. (2000). Detection of extended-spectrum beta-lactamases in Klebsiellae with the Oxoid combination disk method. Journal of Clinical Microbiology 38, Suppl. 11, 4228–32.

Cetinkaya, Y., Falk, P. & Mayhall, C. G. (2000). Vancomycin-Resistant Enterococci. Clinical Microbiology Reviews 13, Suppl. 4, 686–707.

CJD Incidents Panel. (2001). Management of possible exposure to CJD through medical procedures. A consultation paper.  Department of Health. [Online]. Available at: http://www.doh.gov.uk/cjd/consultation

Collie, D. A., Sellar, R. J., Zeidler, M., Colchester, A. C., Knight, R. & Will, R. G. (2001). MRI of Creutzfeldt-Jakob disease: imaging features and recommended MRI protocol. Clinical Radiology 56, Suppl. 9, 726–39.

Collinge, J., Beck, J., Campbell, T., Estibeiro, K. & Will, R. G. (1996). Prion protein gene analysis in new variant cases of Creutzfeldt-Jakob disease. Lancet 348, Suppl. 9019, 56.

Combined Working Party of the British Society for Antimicrobial Chemotherapy, the Hospital Infection Society and the Infection Control Nurses Association. (1998). Revised methicillin-resistant Staphylococcus aureus infection control guidelines for hospitals Journal of Hospital Infection 39, Suppl. 4, 253–90. [Online]. Available at: http://www.his.org.uk/work/mrsa21.doc.

Department of Health (2000). UK antimicrobial resistance strategy and action plan. Available at: http://www.doh.gov.uk/arbstrat.htm.

Drisko, J. A. (2002). The use of antioxidants in transmissible spongiform encephalopathies: a case report. Journal of the American College of Nutrition 21, Suppl. 1, 22–5.

Essack, S. Y. (2000). Treatment options for extended-spectrum beta-lactamase-producers. FEMS Microbiology Letters 190, Suppl. 2, 181–4.

Farmer, T. H., Gilbart, J. & Elson, S. W. (1992). Biochemical basis of mupirocin resistance in strains of Staphylococcus aureus. Journal of Antimicrobial Chemotherapy 30, Suppl. 5, 587–96.

Goff, D. A. & Sierawski, S. J. (2002). Clinical experience of quinupristin/dalfopristin for the treatment of antimicrobial-resistant gram-positive infections. Pharmacotherapy 22, Suppl. 6, 748–58.

Gonzales, R. D., Schreckenberger, P. C., Graham. M. B., Kelkar, S., DenBesten, K. & Quinn, J. P. (2001). Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 357, Suppl. 9263, 1179.

Hawkey, P. M. (1998). The origins and molecular basis of antibiotic resistance. British Medical Journal 317, 657–60.

Heritage, J., M-Zali, F. H., Gascoyne-Binzi, D., Hawkey, P. M. (1999). Evolution and spread of SHV extended-spectrum beta-lactamases in Gram-negative bacteria. Journal of Antimicrobial Chemotherapy. 44, Suppl. 3, 309–18.

Herman, D. J. & Gerding, D. N. (1991). Antimicrobial resistance among enterococci. Antimicrobial Agents and Chemotherapy 35, Suppl. 1, 1–4.

Hill, A. F., Butterworth, R. J., Joiner, S., Jackson, G., Rossor, M. N., Thomas, D. J. et al. (1999). Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy samples. Lancet 353, Suppl. 9148, 183–9.

Johnson, A. P. (1998). Intermediate vancomycin resistance in Staphylococcus aureus: a major threat or a minor inconvenience? Journal of Antimicrobial Chemotherapy 42, Suppl. 3, 289–91.

Joint Tuberculosis Committee and the British Thoracic Society in 2000. Control and prevention of tuberculosis in the United Kingdom: code of practice 2000. Thorax 55, Suppl. 11, 887–901. [Online]. Available at: http://www.brit-thoracic.org.uk/pdf/TB.pdf.

Knothe, H., Shah, P., Krcmery, V., Antal, M. & Mitsuhashi, S. (1983). Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens.  Infection 11, Suppl. 6, 315–7.

Korth, C., May, B. C. H., Cohen, F. E. & Pruisner, S. B. (2001). Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proceedings of the National Academy of Sciences 98, Suppl. 17, 9836–41.

Livermore, D. M. & Brown, D. F. (2001). Detection to beta-lactamase-mediated resistance. Journal of Antimicrobial Chemotherapy 48, Suppl. S1, 59–64.

Livermore, D.M. (1995). beta-Lactamases in laboratory and clinical resistance. Clinical Microbiology Reviews 8, Suppl. 4, 557–84.

Magee, J. T. (2001). Antibiotic resistance and prescribing in the community. Reviews in Medical Microbiology 12, Suppl. 2, 87–96.

Maskell, J. P., Sefton, A. M. & Hall, L. M. (1997). Mechanism of sulfonamide resistance in clinical isolates of Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy 41, Suppl. 10, 2121–6.

Michel, M. & Gutmann, L. (1997). Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: therapeutic realities and possibilities. Lancet 349, Suppl. 9069, 1901–6.

Murray, B. E. (2000). Vancomycin-resistant enterococcal infections. New England Journal of Medicine 342, Suppl. 10, 710–21.

Musser, J. M. (1995). Antimicrobial agent resistance in mycobacteria: molecular genetic insights. Clinical Microbiology Reviews 8, Suppl 4, 496–514.

Patel, R. Mechanism of Glycopeptide Resistance in GRE. 3rd International Symposium of Antimicrobial Resistance. April 12–13, 2001. [Online]. Available at: http://www.ansorp.org/isaar/2001/blue/15.pdf.

Prusiner, S. B. (1997).  Prion diseases and the BSE crisis.  Science 278, 245-51.

Prusiner, S. B. (1998). Prions. Proceedings of the National Academy of Sciences 95, Suppl. 23, 13363–83.

Putman, M., van Veen, H. W., Degener, J. E. & Konings, W. N. (2001). The lactococcal secondary multidrug transporter LmrP confers resistance to lincosamindes, macrolides, streptogramins and tetracyclines. Microbiology 147, Suppl. 10, 2873–80.

Rice, L. B. (2000). Bacterial monopolists: the bundling and dissemination of antimicrobial resistance genes in gram-positive bacteria. Clinical Infectious Diseases 31, Suppl. 3, 762–9.

Scotton, P. G., Rigoli, R. & Vaglia, A. (2002). Combination of quinupristin/dalfopristin and glycopeptide in severe methicillin-resistant staphylococcal infections failing previous glycopeptide regimens. Infection 30, Suppl. 3, 161–3.

Somoskovi, A., Parsons, L. M. & Salfinger, M. (2001). The molecular basis of resistance to isoniazid, rifampin and pyrazinamide in Mycobacterium tuberculosis. Respiratory research 2, 164–8. [Online] Available at: http://respiratory-research.com/content/pdf/rr–2–3–164.pdf.

Standing Medical Advisory Committee. Sub-Group on Antimicrobial Resistance (1998). The path of least resistance. Department of Health. [Online]. Available at: http://www.doh.gov.uk/smacful.htm.

The BSE Inquiry. (1997). [Online]. Available at: http://www.bse.org.uk/.

The Interdepartmental Working Group on Tuberculosis.  The prevention and control of tuberculosis in the United Kingdom (1998). Department of Health. [Online]. Available at: http://www.doh.gov.uk/tbguide.htm.

The National CJD Surveillance Unit, Edinburgh & Department of Infectious and Tropical Disease, London School of Hygiene and Tropical Medicine, London. (2001). Creutzfeldt-Jakob Disease Surveillance in the UK. 10th Annual Report. [Online]. Available at: http://www.cjd.ed.ac.uk/rep2001.html.

Uttley, A. H. C., Collins, C. H., Naidoo, J. & George, R. C. (1988). Vancomycin-resistant enterococci. Lancet 1, Suppl. 8575–6, 57–8.

Wadsworth, J. D., Joiner, S., Hill, A. F., Campbell, T. A., Desbrulais, M., Luthbert, P. J. et al. (2001). Tissue distribution of protease resistant prion protein in variant Creutzfeldt-Jakob disease using a highly sensitive immunoblotting assay. Lancet 358, Suppl. 9277, 171–80.

WHO. (2001). Report of a WHO consultation. The revision of the surveillance case definition for variant Creutzfeldt-Jakob disease (vCJD), 17 May 2001, Edinburgh, United Kingdom. [Online]. Available at: http://www.who.int/emc-documents/tse/whocdscsreph20015.htm.